Market news

CRISPR Therapeutics AG remains a long-term Buy, anchored by Casgevy's success and management’s execution in ex vivo gene editing. Click for more on CRSP.

Gene editing stocks fall as Anthropic’s (ANTHRO) AI model Claude discovers a new enzyme system similar to the gene-editing tool CRISPR. Read more here.

CRISPR Therapeutics owns the only approved gene therapy of its kind, yet the stock sits far below where Wall Street thinks it belongs. One analyst sees a path to gains that would embarrass the broader market, but the numbers tell a complicated story.

Boost ROI via rare-disease R&D, CRISPR therapies, scalable manufacturing, CDMO partnerships and regulatory incentives that accelerate approvals and commercialization. Autologous Hematopoietic Stem Cell Gene Therapy Market Autologous Hematopoietic Stem Cell Gene Therapy Market Dublin, Sept. 23, 2026 (GLOBE NEWSWIRE) -- "Autologous Hematopoietic Stem Cell Gene Therapy Market Global Report 2026" has been added to ResearchAndMarkets.com's offering. Autologous Hematopoietic Stem Cell Gene Therapy Mar

CRISPR Therapeutics AG (CRSP) closed at $59.03 in the latest trading session, marking a +1.2% move from the prior day.

With a medicine on the market and plenty of projects in the pipeline, this company's trajectory could be very positive for investors without being a smooth ride.

The average brokerage recommendation (ABR) for CRISPR Therapeutics (CRSP) is equivalent to a Buy. The overly optimistic recommendations of Wall Street analysts make the effectiveness of this highly sought-after metric questionable. So, is it worth buying the stock?

CRISPR Therapeutics (CRSP) is drawing fresh attention as investors digest management’s recent comments on faster CASGEVY uptake and prepare for an earnings update that is expected to show higher revenue and a smaller loss. CRISPR Therapeutics has seen momentum cool recently, with the share price down 5.4% over the past week and 3.2% over the last month, while the 1-year total shareholder return has declined 15.3%. This follows a 3-year total shareholder return of 9.3% and a 5-year total...

CRISPR Therapeutics AG (CRSP) reached $51.8 at the closing of the latest trading day, reflecting a -2.19% change compared to its last close.

CRISPR Therapeutics (CRSP) has received quite a bit of attention from Zacks.com users lately. Therefore, it is wise to be aware of the facts that can impact the stock's prospects.

The company had fallen out of investor favor; its recovery was impressive.

CRISPR's expanding pipeline could unlock significantly more value by 2031.

CRISPR Therapeutics stock has climbed in the shorter term but still carries a heavy five year loss, and current valuation checks point to a company that does not clearly screen as either cheap or expensive. For investors looking at CRISPR Therapeutics today, the share price near US$56.82 sits against a mixed valuation read and a long term track record that remains in the red. The stock has fallen 52.9% over 5 years, which means long term holders are still under water despite more recent...

CRISPR Therapeutics (CRSP) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.

Detailed price information for Ascendis Pharma ADR (ASND-Q) from The Globe and Mail including charting and trades.

Detailed price information for Crispr Therapeutics Ag (CRSP-Q) from The Globe and Mail including charting and trades.

An experimental CRISPR-based gene-editing therapy could be a one-and-done treatment for high cholesterol and high triglycerides, a study suggests.

-Data presented in a late-breaking presentation at the European Society of Cardiology (ESC) Congress 2026- -Phase 1a clinical data for CTX310® continued to demonstrate robust, dose-dependent reductions in circulating ANGPTL3 with a mean reduction from baseline of 79% (maximum 89%), a mean reduction in triglycerides (TG) of 48% (maximum 78%), and a mean reduction of low-density lipoprotein (LDL) of 53% (maximum 84%) at the highest dose- -CTX310 was well tolerated with no treatment-related serious

This year, the biotech stock has underperformed both the Nasdaq Biotechnology Index and the S&P 500.

Detailed price information for Crispr Therapeutics Ag (CRSP-Q) from The Globe and Mail including charting and trades.

Detailed price information for Crispr Therapeutics Ag (CRSP-Q) from The Globe and Mail including charting and trades.

Detailed price information for Crispr Therapeutics Ag (CRSP-Q) from The Globe and Mail including charting and trades.

Crispr Therapeutics (CRSP) reported a relatively quiet Q2, with Casgevy continuing to gain commercia

CRSP reports a narrower-than-expected Q2 loss. Revenues beat estimates as Casgevy sales surge across global markets and clinical programs advance.

CRISPR Therapeutics (CRSP) delivered earnings and revenue surprises of +14.55% and +37.28%, respectively, for the quarter ended June 2026. Do the numbers hold clues to what lies ahead for the stock?

ZUG, Switzerland and BOSTON, Aug. 03, 2026 (GLOBE NEWSWIRE) -- CRISPR Therapeutics (Nasdaq: CRSP) today reported financial results for the second quarter ended June 30, 2026. "The second quarter reflected strong execution across CRISPR Therapeutics' portfolio and platform," said Samarth Kulkarni, Ph.D., Chairman and Chief Executive Officer of CRISPR Therapeutics. "CASGEVY's momentum continued to build, highlighted by the FDA's approval for children as young as 2 years old, while we expanded our

CRISPR Therapeutics Stock Reaction To Recent Trading Session CRISPR Therapeutics (NasdaqGM:CRSP) recently finished a trading session with a positive price move that outpaced the S&P 500. The stock is drawing attention as investors look ahead to its upcoming earnings report. See our latest analysis for CRISPR Therapeutics. At a share price of US$47.99, CRISPR Therapeutics has seen short term momentum cool, with a 30 day share price return down 13.72% and a 1 year total shareholder return down...

The next six months may be decisive for the biotech.

CRISPR Therapeutics AG (CRSP) closed the most recent trading day at $48.44, moving +1.68% from the previous trading session.

Recently, Zacks.com users have been paying close attention to CRISPR Therapeutics (CRSP). This makes it worthwhile to examine what the stock has in store.

CRISPR Therapeutics (CRSP) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

In the most recent trading session, CRISPR Therapeutics AG (CRSP) closed at $46.54, indicating a -2.08% shift from the previous trading day.

Detailed price information for Crispr Therapeutics Ag (CRSP-Q) from The Globe and Mail including charting and trades.